Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Summary Background Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2014-09, Vol.15 (10), p.1090-1099
Hauptverfasser: Burger, Jan A, Dr, Keating, Michael J, Prof, Wierda, William G, Prof, Hartmann, Elena, MD, Hoellenriegel, Julia, MS, Rosin, Nathalie Y, PhD, de Weerdt, Iris, MD, Jeyakumar, Ghayathri, MD, Ferrajoli, Alessandra, MD, Cardenas-Turanzas, Marylou, PhD, Lerner, Susan, MS, Jorgensen, Jeffrey L, MD, Nogueras-González, Graciela M, MS, Zacharian, Gracy, MS, Huang, Xuelin, PhD, Kantarjian, Hagop, Prof, Garg, Naveen, MD, Rosenwald, Andreas, Prof, O'Brien, Susan, Prof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!